4-amino-N-(m-tolyl)benzenesulfonamide | 16803-94-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N-(m-tolyl)benzenesulfonamide
• 英文别名: 4-amino-N-(3-methylphenyl)benzenesulfonamide
• CAS: 16803-94-4
• 化学式: C₁₃H₁₄N₂O₂S
• mdl: MFCD01140091
• 分子量: 262.332
• InChiKey: CRRQLCIJVYKQSO-UHFFFAOYSA-N

物化性质

• 熔点：
  135 °C
• 沸点：
  452.0±55.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4-amino-N-(m-tolyl)benzenesulfonamide 在 溴 作用下， 以 氯仿 为溶剂， 反应 10.0h， 生成 coumarin-3N-(4'-(N'-p-bromo-m-methylphenyl)sulphonamidophenyl)carboxamide
  参考文献：
  名称：

  Bedair, A. H.; Aly, F. M.; El-Assy, R. K. M., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1987, vol. 26, p. 91 - 94

  摘要：

  DOI：
• 作为产物：
  描述：

  N-acetyl-sulfanilic acid m-toluidide 在 sodium hydroxide 作用下， 生成 4-amino-N-(m-tolyl)benzenesulfonamide
  参考文献：
  名称：

  Behnisch, Chemische Berichte, 1948, vol. 81, p. 297,302

  摘要：

  DOI：

文献信息

• [EN] QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER<br/>[FR] DÉRIVÉS DE QUINOLÉINE ET LEURS UTILISATIONS DANS LA GESTION DU CANCER
  申请人：UNIV EMORY

  公开号：WO2021050721A1

  公开（公告）日：2021-03-18

  Provided herein are compounds, pharmaceutical compositions including such compounds, and methods of using such compounds to treat diseases or disorders associated with MDM2 activity.

  本文提供了化合物、包括这些化合物的药物组合物，以及使用这些化合物治疗与MDM2活性相关的疾病或紊乱的方法。
• Pyridazine and its related compounds. Part 36. Synthesis and antimicrobial activity of some novel pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine derivatives
  作者：Ali Deeb、Sebaey Mahgoub

  DOI：10.1007/s00044-014-1011-3

  日期：2014.10

  Novel derivatives of pyrimidothienopyridazine were designed and synthesized through a versatile method. Some of the target compounds bearing the sulfonamide group were evaluated for their antimicrobial activity against representative Gram-positive bacteria, Gram-negative bacteria, and fungi by applying the agar plate diffusion technique. The results showed that derivatives 11a have promising inhibitory

  通过通用方法设计并合成了嘧啶并噻吩并哒嗪的新型衍生物。通过应用琼脂平板扩散技术，评估了一些带有磺酰胺基的目标化合物对代表性的革兰氏阳性菌，革兰氏阴性菌和真菌的抗菌活性。结果表明，衍生物11a具有对革兰氏阳性细菌的有希望的抑制活性，衍生物11b和11e也具有对真菌的有效抑制作用。其余化合物对被检微生物表现出中等至低活性。
• PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS
  申请人：Lawrence Harshani

  公开号：US20110201609A1

  公开（公告）日：2011-08-18

  The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds. In one embodiment, a compound of the invention has the chemical structure shown in formula I: wherein R 1 is an organic cyclic ring structure bonded to a sulfonamide structure; R 2 is H, halogen, alkyl, —NR 6 R 7 , or heteroalkyl; R 3 is H, halogen, —OH, —O-alkyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —NO 2 , —NH 2 or substituted amines; R 4 is H, alkyl, heteroalkyl, aryl, or heteroaryl, any of which can be optionally substituted with one or more of —NO 2 , alkyl, heteroalkyl, aryl, or heteroaryl, or halogen; R 5 is H, —OH, halogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —O-alkyl, —O-aryl, heteroalkyl, —NO 2 , —NH 2 , or substituted amine; and R 6 and R 7 are independently H, O, alkyl, aryl, heterocycloalkyl, or heteroaryl, or together can form a heterocycloalkyl or a heteroaryl, any of which can be optionally substituted with one or more of —NO 2 , alkyl, heteroalkyl, aryl, or halogen; or a pharmaceutically acceptable salt or hydrate thereof. In another embodiment, a compound of the invention has the chemical structure shown in formula II: wherein Q, W, X, Y, Z are each independently carbon, oxygen, or nitrogen; R 1 is H, or X 1 R 8 ; R 2 is heteroalkyl, which can be optionally substituted with one or more of —OH, halogen, —C(O)OR 4 , alkyl, heteroalkyl, heterocycloalkyl, or heteroaryl; R 3 is heterocycloalkyl, aryl, heteroaryl, any of which can be optionally substituted with one or more of a halogen or —OH; and R 4 is H or alkyl; R 5 is halogen, alkyl or nitro; R 6 is nitro, X 2 R 9 or a halogen; R 7 is H or alkyl; R 8 is H, alkyl, aryl, CH 2 -alkyl-aryl, -alkyl-C(O)OH, or alkyl-tetrazole (aromatic and aliphatic heterocyclic groups); R 9 is H or alkyl; X 1 is oxygen, nitrogen, or sulfur; X 2 is oxygen, nitrogen, or sulfur; or a pharmaceutically acceptable salt or hydrate thereof.

  本发明涉及作为蛋白酶体抑制剂的化合物及使用该化合物的方法。在一种实施方式中，本发明的化合物具有公式I所示的化学结构：其中，R1是与磺酰胺结构键合的有机环状环结构；R2是H、卤素、烷基、-NR6R7或杂环烷基；R3是H、卤素、-OH、-O-烷基、烷基、环烷基、杂环烷基、芳基、杂芳基、-NO2、-NH2或取代胺；R4是H、烷基、杂烷基、芳基或杂芳基，其中任何一个都可以选择性地取代一个或多个-NO2、烷基、杂烷基、芳基或杂芳基或卤素；R5是H、-OH、卤素、烷基、芳基、杂芳基、环烷基、杂环烷基、-O-烷基、-O-芳基、杂烷基、-NO2、-NH2或取代胺；R6和R7分别是H、O、烷基、芳基、杂环烷基或杂芳基，或者一起形成杂环烷基或杂芳基，其中任何一个都可以选择性地取代一个或多个-NO2、烷基、杂烷基、芳基或卤素；或其药学上可接受的盐或水合物。在另一种实施方式中，本发明的化合物具有公式II所示的化学结构：其中，Q、W、X、Y、Z分别独立地是碳、氧或氮；R1是H或X1R8；R2是杂环烷基，可以选择性地取代一个或多个-OH、卤素、-C（O）OR4、烷基、杂烷基、杂环烷基或杂芳基；R3是杂环烷基、芳基、杂芳基，其中任何一个都可以选择性地取代一个或多个卤素或-OH；R4是H或烷基；R5是卤素、烷基或硝基；R6是硝基、X2R9或卤素；R7是H或烷基；R8是H、烷基、芳基、CH2-烷基-芳基、-烷基-C（O）OH或烷基-四唑（芳香和脂肪族杂环基）；R9是H或烷基；X1是氧、氮或硫；X2是氧、氮或硫；或其药学上可接受的盐或水合物。
• Marchant; Lucas; McClelland, Canadian Journal of Research, Section B: Chemical Sciences, 1942, vol. 20, p. 5,7, 9
  作者：Marchant、Lucas、McClelland

  DOI：——

  日期：——
• Synthesis and in vitro microbial activities of amides of pyridoquinolone
  作者：Navin B. Patel、Sarvil D. Patel、Hiren I. Chauhan

  DOI：10.1007/s00044-010-9443-x

  日期：2011.9

  In this study, we report the antimicrobial evaluation of newly synthesized amides of pyridoquinolones from substituted aniline, substituted phenyl thioureas and 4-amino-N-(substitutedphenyl)benzenesulfonamide. Structures of selected compounds have been established by IR and H-1 NMR spectra and elemental analysis. The structure-activity releationships have been studied by screening of antimicrobial activity over S. aureus, B. subtilis, E. coli, P. aeruginosa, and C. albicans using cup-plate method.